Publications in collaboration with researchers from Probity Medical Research (3)

2013

  1. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 1, pp. 83-88

2012

  1. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

2009

  1. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 976-986